Table 4.
Association Between Aspirin Use and Bleeding Events, Stratified by Lipoprotein(a) Level
| Lipoprotein(a) ≤50 mg/dL (n=5100) | Lipoprotein(a) >50 mg/dL (n=1261) | |
|---|---|---|
| Major bleeding events | 667 | 197 |
| HR | 95% CI | P value | HR | 95% CI | P value | |
|---|---|---|---|---|---|---|
| Aspirin use | ||||||
| Unadjusted | 1.51 | 1.27–1.80 | <0.001 | 1.49 | 1.09–2.04 | 0.013 |
| Adjusted* | 1.08 | 0.90–1.29 | 0.439 | 1.21 | 0.86–1.69 | 0.265 |
| Gastrointestinal bleeding events | 266 | 91 | ||||
| HR | 95% CI | P value | HR | 95% CI | P value | |
|---|---|---|---|---|---|---|
| Aspirin use | ||||||
| Unadjusted | 1.69 | 1.29–2.20 | <0.001 | 1.25 | 0.77–2.01 | 0.368 |
| Adjusted* | 1.18 | 0.89–1.56 | 0.252 | 1.14 | 0.69–1.91 | 0.604 |
*
Adjusted for age, sex, race/ethnicity, liver disease, hypertension treatment, nonsteroidal anti‐inflammatory drug use, oral anticoagulant use, alcohol use, systolic blood pressure, and estimated glomerular filtration rate. HR indicates hazard ratio.